CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. by Trabanelli, S. et al.
CD127+ innate lymphoid cells are dysregulated in
treatment naïve acute myeloid leukemia patients at
diagnosis
Innate lymphoid cells (ILCs), defined as lineage negative
(Lin–) CD127+ cells, have emerged as novel important
immune effector cells, playing a critical role also in tumor
immunosurveillance.1-5 Recently, it was shown that the
number of ILCs in acute myeloid leukemia (AML) patients
is significantly reduced after chemotherapy/radiotherapy as
compared to healthy donors.6 However, so far, no data on
ILC frequency, subset distribution and function in AML
treatment naïve patients are available. Therefore, we ana-
lyzed the frequency, subset distribution and function of
ILCs in AML patients before any treatment, a parameter
that is of paramount importance to understand the role of
ILCs during leukemogenesis and to assess the impact of
current treatments on these cells.
ILCs are a novel family of lineage negative CD127+
innate immune cells belonging to the lymphoid lineage, yet
not expressing rearranged antigen specific receptors.
Instead, they are activated and regulated mainly by
cytokine mediated signals. To date, three distinct subsets of
ILCs have been described, based on their transcriptional
regulation and cytokine profiles that mirror those of T-
helper subsets: ILC1, expressing T-bet and producing IFN-γ
and TNF-α, ILC2, expressing GATA-3 and secreting IL-4, 
-5, -13 and ILC3, expressing Rorγt and secreting IL-17A
and/or IL-22.7,8 Although a population of ILCs CD127dim/- has
recently been described,9 here we focused on circulating
ILC populations that are CD127+ in peripheral blood (PB).
We identified ILCs within the PB lymphocyte region by
multicolor flow cytometry, on the basis of their forward
(FSC) and side scatter (SSC) profiles (FSC low and SSC low)
and by excluding from the analysis doublets (FSC H/FSC W
dot plot, followed by SSC A/SSC W dot plot) and dead cells
[positive for ViViD LIVE/DEAD fixable dead cell stain kit
(LifeTechnologies)]. Total ILCs were gated as Lin–CD127+
cells. Subsequently, ILC1 were identified as
CRTH2–cKit–CD56– cells, ILC2 as CRTH2+cKit+/- cells, ILC3
NCR+ as CRTH2–cKit+NKp46+ cells and ILC3 NCR– as
CRTH2–cKit+NKp46– cells, as described by Spits et al.7 A
minimum of 106 MNCs was acquired on a Gallios flow
cytometer (Beckman Coulter). Data were analyzed using
FlowJoTM software (TreeStar). Statistical analysis was per-
formed using t-tests or ANOVAs.
We compared the frequency of total ILCs in PB samples
from 38 age- and sex-matched healthy subjects and 38
newly diagnosed AML patients [(median age 61, range 21-
79; sex ratio (M:F) 21:17; primary AML 38 of 38 (100%);
hyperleukocytosis 21 of 38 (55.3%); cytogenetic risk group:
low 6 of 38 (15.8%), intermediate 22 of 38 (57.9%), high
10 of 38 (26.3%)]. All patients provided written informed
consent (EMATC-2013-01 or approval by the local ethical
committee of the Canton of Bern, Switzerland), and the
research was conducted in accordance with the Declaration
of Helsinki. Remarkably, we measured a highly significant
reduction of circulating ILCs in patients at disease onset
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Figure 1. Innate lymphoid cells frequency and subtypes in AML patients at diagnosis. Total circulating ILCs were identified as Lineage
[(FITC-conjugated anti-CD3, anti-CD4, anti-CD14, anti-CD16, anti-CD19 (Beckman Coulter), anti-CD8, anti-CD15 (AbD Serotech), anti-CD20,
anti-CD33, anti-CD34, anti-CD203c and anti-FceRI (BioLegend)] negative CD127+ (PerCP-Cy5.5- or Brilliant Violet 421-conjugated anti-
CD127 (BioLegend)] lymphocytes. Since a non-negligible proportion of ILC3 can express CD56,10 we excluded this marker from the lineage
cocktail. (A) Representative example of the gating strategy to determine, by multiparameter flow cytometry, in healthy donors (HD) and
AML patients, the percentage (B) and the absolute number (C) of total circulating ILCs. Histograms represent the mean ± SEM of total
Lin–CD127+ ILCs in PB of healthy subjects and AML patients. (D) Correlation between the number of circulating ILCs and the percentage
of circulating blasts. (E) Representative example of the gating strategy to determine ILC1, ILC2 and ILC3 according to CRTH2 versus cKit
expression and subsequent evaluation of T-bet expression (PE CF594-conjugated) in ILC1, GATA-3 (PE-Cy7-conjugated) in ILC2 and Rorγt
(PE-conjugated) in ILC3 (all from BD Pharmingen) of one representative healthy donor. In clear gray the histogram of the isotype control.
ILC subsets were identified as previously described,7 by using PE CF594- or Brilliant Violet 421-conjugated anti-CRTH2 (BD Pharmingen);
PerCP-Cy5.5- or PE-Cy7-conjugated anti-NKp46; PE– or APC-conjugated anti-cKit; APC-eFluor780-conjugated anti-CD56 (eBioscience). (F
and G) Histograms represent the mean ± SEM of the percentage of ILC subsets within total Lin–CD127+ ILCs of healthy donors and AML
patients at diagnosis (F), or of BM and PB of AML paired samples at diagnosis (G), setting total ILCs as the 100%. **P<0.01; ***P<0.001. 
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Figure 2. Cytokine production by ILCs in AML patients at diagnosis. (A and B) MNCs were stimulated ex vivo for 3 h, then the intracellular
staining was performed using PE-conjugated anti-IL-17A, PerCP-conjugated anti-IL-22, PE-Cy7-conjugated anti-IFN-γ, APC-conjugated anti-
IL-5 and IL-13, Alexa700-conjugated anti-TNF-α (BD Pharmingen). (A) Representative result of the intracellular staining by gating on total
ILCs (Lin–CD127+ cells). (B) Histograms represent the mean ± SEM of the percentage of ILCs (Lin–CD127+ cells) in healthy subjects and
AML patients (n=15), producing IFN-γ, TNF-α, IL-5 plus IL-13, IL-17A and IL-22. ** and *** represent significant comparisons with P<0.01
and <0.001, respectively. (C and D) MNCs enriched in ILCs (i.e. MNCs depleted from CD14+/CD33+/CD8+/CD4+ cells) were incubated with
target cells (i.e. allogeneic/autologous blasts) overnight at 37°C, in medium without cytokines, at an optimized effector:target ratio of
1:10. The ratio was calculated based on the percentage of flow-cytometry determined frequency of ILCs in CD14–CD33–CD8–CD4– MNCs.
As negative control, CD14–CD33–CD8–CD4– MNCs were incubated without targets. BrefeldinA was added to the cultures at incubation
onset. After 16 h cells were washed and stained. (C) Representative result of the intracellular staining by gating on total ILCs (Lin–CD127+
cells) obtained from one leukemic patient. (D) Histograms represent the mean ± SEM of the percentage of ILCs (Lin–CD127+ cells), in
healthy subjects and AML patients (n=4), producing IFN-γ, TNF-α and IL-5 plus IL-13. **P<0.01; ***P<0.001. 
Figure 3. ILC frequency in AML patients responding to chemotherapy. Histograms represent the mean ± SEM of the percentage of (A) total
Lin–CD127+ ILCs and (B) ILC1 and ILC3 NCR+ in AML patients at diagnosis and in AML patients responding to therapy (AML Resp). Dashed
lines represent the mean value observed in control healthy donors. **** represent significant comparisons with P<0.0001 (Tukey cor-
rected for multiple comparisons). **P<0.01; ***P<0.001. 
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compared to controls both in percentage and absolute
number (Figure 1A-C). Moreover, we found a positive cor-
relation between the number of circulating ILCs and the
percentage of circulating leukemic blasts (R2=0.3477,
P=0.0031) (Figure 1D). Then, we analyzed the relative fre-
quency of the different ILC subsets, characterized by the
combination of surface marker expression detailed above
and of specific transcription factors: T-bet for ILC1, GATA-
3 for ILC2 and Rorγt for ILC3 (Figure 1E). Strikingly, we
found a significant enrichment of ILC1 in AML patients and
a concomitant profound reduction of ILC3 NCR+ cells. No
differences were detectable in the levels of ILC2 and ILC3
NCR– cells (Figure 1F). No difference was observed either in
the frequency of total circulating ILCs and in the distribu-
tion of the ILC subsets among the three cytogenetic risk
groups (data not shown). In addition, since AML is a malig-
nancy originating in the bone marrow (BM), we compared
the frequencies of ILCs between paired BM and PB samples
from 17 patients. We did not find any difference either in
percentage of total ILCs (data not shown), or in the relative
proportions of the different ILC subsets (Figure 1G), sug-
gesting a similar composition of ILCs in BM and PB in AML
patients at disease onset. To test the functionality of ILCs
in terms of their capacity to produce type 1 (IFN-γ and TNF-
α), type 2 (IL-5 plus IL-13) and type 3 (IL-17A and IL-22)
cytokines, we stimulated MNCs with 1 mg/mL PMA plus
0.5 mg/mL Ionomycin, in the presence of BrefeldinA
(Sigma-Aldrich), for 3 h and stained them for intracellular
cytokine production. Following this direct ex vivo short-
term activation, ILCs of AML patients were dramatically
impaired in their production of IFN-γ, TNF-α as well as type
2 cytokines (e.g. IL-5/IL-13) as compared to ILCs of healthy
subjects, while we found no difference in type 3 cytokines
(e.g. IL-17A and IL-22) (Figure 2A and B). Moreover, in
order to assess the role the ILCs might have in vivo, we used
fresh PB of 4 newly diagnosed AML patients and, by adapt-
ing a method recently described,11 we isolated AML blasts
from MNCs using a monoclonal antibody cocktail against
CD14 and CD33 (Miltenyi). Then, we depleted the
CD14–CD33– MNCs’ flow through fraction from CD4+ and
CD8+ cells so as to obtain MNCs that are both depleted of
leukemic cells, and enriched in ILCs. It was seen that ILC-
enriched MNCs, of both healthy donors and leukemic
patients, incubated with target cells (i.e. blasts) are able to
produce cytokines in response to respectively allogeneic or
autologous blasts (Figure 2C and D). 
Even if we cannot exclude the involvement of alloreac-
tivity in the recognition of leukemic blasts by ILCs from
healthy donors, our data suggest that ILCs from AML
patients could be impaired in the production of IFN-γ or
type 2 cytokines in comparison to ILCs from healthy
donors. Of note, the capacity of ILCs from AML patients to
produce TNF-α in response to autologous blasts suggest
that ILCs might be able to control, through the 
TNF-α/TNF-R1 pathway, the leukemic cell growth/sur-
vival.12
Finally, we compared the percentage of total circulating
ILCs in AML patients (n=9) responding to standard
chemotherapy (2 cycles of daunorubicin/cytarabine) with
that of patients at diagnosis and of healthy donors [F (2,
82)=56.26; P<0.0001]. The percentage of total ILCs is com-
pletely recovered in responding patients (Figure 3A). In
addition, we asked if also ILC1 and ILC3 NCR+ cells, the
subsets dysregulated at diagnosis, were recovered in
responding patients. While ILC1 were still increased in
comparison to healthy donors, ILC3 NCR+ cells were
restored to normal levels [(F (2, 82) = 28.28; P<0.0001)
(Figure 3B)].
Overall, we show here for the first time that ILCs are sig-
nificantly dysregulated at diagnosis in terms of: i) frequen-
cy; ii) subtype composition; and iii) function in treatment
naïve AML patients. Moreover, we show here that ILCs are
partially recovered in patients responsive to therapy, sug-
gesting that ILC dysregulation is associated with the dis-
ease itself and is not just a consequence of chemotherapy.
It is noteworthy that, in AML patients, the circulating ILC
pool accurately reflects the ILC dysregulation occurring in
their paired bone marrow samples. 
Our findings extend previously published work by
Munneke et al.6 on changes in blood innate lymphoid cells
in patients with AML. Indeed, their work was focused on
the correlation between ILC recovery and the decreased
susceptibility to develop mucositis/acute graft-versus-host
disease in AML patients receiving treatments. However,
the comparison was between treated AML patients and
healthy donors, lacking data on treatment-naïve AML
patients. Therefore, our findings establish, for the first time
in AML patients at diagnosis, base-line reference values for
ILC frequency and function, as well as the ILC subtype dis-
tribution. These values may represent a useful benchmark
to assess the effect of anti-cancer treatments on ILC num-
ber or function. However, while our work in conjunction
with that by Munneke et al.6 strongly suggests the interest-
ing possibility that ILCs may be implicated in the pathogen-
esis and progression of human AML, the significance of ILC
dysregulation in number and of their functional impair-
ment in AML awaits further investigation.
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